ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VAL Valirx Plc

3.10
-0.20 (-6.06%)
08 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Valirx Plc LSE:VAL London Ordinary Share GB00BLH13C52 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.20 -6.06% 3.10 3.00 3.20 3.30 3.05 3.30 872,250 15:36:39
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 0 -2.37M -0.0262 -1.18 2.8M
Valirx Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker VAL. The last closing price for Valirx was 3.30p. Over the last year, Valirx shares have traded in a share price range of 3.05p to 14.75p.

Valirx currently has 90,174,156 shares in issue. The market capitalisation of Valirx is £2.80 million. Valirx has a price to earnings ratio (PE ratio) of -1.18.

Valirx Share Discussion Threads

Showing 26976 to 26997 of 29350 messages
Chat Pages: Latest  1090  1089  1088  1087  1086  1085  1084  1083  1082  1081  1080  1079  Older
DateSubjectAuthorDiscuss
20/6/2023
13:16
Big buyer knows funds are ok for a year and more than likely knows there’s some good new pre agm.
412069
20/6/2023
11:54
I think we have funds well in to 2024 plus THX money and the lab income. GLA
wulber
20/6/2023
11:18
THE VALIRX PLACING SWEEP

Roll up roll up.

Let’s have a comp to see what price the placing will be done at. We know it’s coming so we may as well have a bit of fun

I’m in at 4p
Porky think you mentioned 5p

Any other prices .

francoismyname
20/6/2023
10:30
Lol sooty :)
ben gibbons
20/6/2023
10:20
Trouble is Ben we have a board full of monkeys
sooty snipes
20/6/2023
10:11
Not interested in what some plum on LSE says.

I am interested in what the ceo of the company says.

That post is from a conversation I had with Suzy this morning regarding Satu and oncobone.

Besides Satu resigned from oncobone in April 2023.

To much noise being made here and on LSE.

Listen to the organ grinder not the monkeys!

ben gibbons
20/6/2023
09:27
Read ironmighty post 09:23 on lse for confirmation mr ben 😂
jasonpugh
20/6/2023
08:49
Just for clarification.see https://oncobone.com/ this is the Finnish company that Val have the agreement with.Oncobone Ventures Limited is a completely different UK based company.DYOR.I see through the lies of the Jedi I do not fear the darkside as you do!
ben gibbons
20/6/2023
06:33
Comms with George Morris last night.
Obviously take with pinch of salt but if true or elements in it are true then valirx in serious trouble with fca.

I sent george the rns from yesterday. His response.
George “they have not communicated at all”
Me. “Thoughts on rns?”
George “ will look when i get a moment been on the road all day”
George. “ that was an unapproved rns with no verification or counterpart sight or agreement. Technically illegal “
Me. “What does satu think?”
George. “Furious along with most of oncobone”
DYOR 🧐. According to satu on her LinkedIn profile she still works for oncobone. But companies house says different. Anyway she has friends at oncobone.
Georges comments requires verification on all points.

jasonpugh
19/6/2023
19:22
Jason. I agree Stella has an attitude but she hasn't been there long enough to hold responsible for the rest of the board. It was probably her that pulled off the deal with Imagen. I think it would be a mistake to vote her off simply because she hasn't bought any shares. To be critical she's right when she says the company lack stability. I think if we could get Adam on board with Stella, Cathy, Zai and Suzy in a scientific role we would be up and running. If we got shut of the board Adam would have to step forward if he wanted to protect his investment.
sooty snipes
19/6/2023
16:08
Fundamentally the three financial stooges need replacing as they have produced zero.
Panu needs to go. She creates great doubt to others and her continued non participation in buying shares is alarming.
Appoint adam to the board as this would instantly double share price and create positive momentum after (no brainer). However there is something sinister about the board not wanting this. It will become apparent very soon.
The inevitable consequence of being stubborn board members are your removal.
The scientists remain. The finance people replaced. Forced via vote. Bolshevik 1917 comes to mind. Show me the palms of your hands board.
Because shareholders want panu to buy her reaction is non compliance. Even if warren buffett advised her to buy now her original prejudice “no shareholders are going to tell me what to do!” Remains. Consequences.
Removal from board and tarnished cv. DYOR

jasonpugh
19/6/2023
15:38
Sooty, it's not what he says but it's the volume. We can all agree or disagree in full or part, but too much copy and paste continuously here and LSE.Porky, we get your point BTW, now leave it please.I visit the BB's to see what new gems of inspiration we have but this is too much and a unhealthy relationship you have.
wulber
19/6/2023
15:12
Porky I don't agree with some of what you have to say but you have the right to say whatever you like. Don't let these oppressors of free speech say otherwise
sooty snipes
19/6/2023
14:40
Porky, please stop the repetition!
wulber
19/6/2023
10:33
you are talking about the old valirix... keep spreading fear!
you want it to fail, just admit it.
Buy

qnq
19/6/2023
10:21
The longer they leave the raise the lower the price will be. People not buying the jam tomorrow mantra as been trotted out for 12 years now over hundreds of RNS’s.

We all know it’s coming. Just get it over and done with. Might as well kitchen sink it and say the THX deal is a dead duck at the same time

francoismyname
19/6/2023
09:54
porky writing at 2am! must be something, he knows some good news coming.
another positive news this morning, Suzie focising on cash generation and not burn. people should not confuse the old valirix with the valirix shes running.
read couple of comments by the two main slaggers (I think I know who they are!) about how the lab idea cant generate money! thats total rubbish. there are companies and its only a handful of them globally that are running trials for pharmas and biitechs. they qre worth in the hundreds of millions.
Buy

qnq
19/6/2023
08:17
@JasonPugh
£7k of assets according to records at Companies House, not sure why it was RNS worthy unless as it’s a contract they thought it worth issuing an RNS to create noise to deflect from the Japan failure?
Market always makes its own opinion anyhow.
Two weeks until AGM then at least we know what the forward board will look like and if it’s 40m or 50m headroom - I cant see the 10m of options getting across the line can you?

porky9
19/6/2023
08:04
Lots of RNS releases at the moment, I wonder why, unfortunately they are not tangible, the market will simply not react, a continuing sh1t show!
pinkpudycat
19/6/2023
07:27
Jason, this a business relationship not a break up and make up, lol.
wulber
19/6/2023
07:20
The rns this morning. Look who is chairman of oncobone ventures ltd. SATU 🧐. According to LinkedIn satu is friends with cathy. Maybe suzy and satu are friends again?
jasonpugh
19/6/2023
07:07
Ooh P9 - day to day positive developments here at VAL as you continue be obsessive are delusional!RNS:Inaphaea has entered into an agreement with the Virtual CRO services company OncoBone Limited ("OncoBone") whereby clients of OncoBone can access Inaphaea services. OncoBone offers a service to virtual biotech and other biopharma clients whereby OncoBone designs and commissions pre-clinical work on behalf of the client. To conduct the laboratory work, OncoBone engages with a range of pre-clinical Contract Research Organisations ("CROs") to execute on the experimental designs that OncoBone has developed. Inaphaea is now confirmed as an OncoBone supplier of cell-based assays.Additionally, Inaphaea is pleased to report that the cell-based assay services are now listed on scientist.com, a database of CROs that can be used by biotechnology and pharmaceutical companies to search for scientific capabilities.
wulber
Chat Pages: Latest  1090  1089  1088  1087  1086  1085  1084  1083  1082  1081  1080  1079  Older

Your Recent History

Delayed Upgrade Clock